Chiauranib for Advanced Solid Malignant Tumors and Relapsed/Refractory SCLC.
Clinical trial NCT05271292 · UNKNOWN
Trial details
- NCT number
- NCT05271292
- Sponsor
- Chipscreen Biosciences, Ltd.
- Status
- UNKNOWN
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2022-08-26
- Primary completion
- 2025-03-01
- Enrollment
- 36
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.